Calla Lily Clinical Care Secures £1.3M to Revolutionize Vaginal Drug Delivery for Women's Health

Calla Lily Clinical Care is thrilled to announce a successful funding round, securing £1,300,000 to drive forward our mission of revolutionizing the delivery of vaginally-administered drugs. As a pioneering British medical device startup, our patented technology is engineered to provide a leak-free, convenient, and dosage-confident solution—particularly for progesterone delivery in miscarriage prevention and IVF treatments. This new capital injection will enable us to meet the rising demand for patient-centric treatment options, especially in light of the significant increase in progesterone prescriptions following the Nov 2021 update to NICE’s miscarriage guidance. The funds will be strategically allocated to enhance our research and development efforts, further streamline our production processes, and expand our clinical validation studies. Our aim is not only to continue refining our delivery platform for better efficacy and user experience but also to accelerate our entry into a broader range of applications, including treatments for menopause and interventions targeting the vaginal microbiome. This funding milestone validates our technology, which has already received FDA clearance and earned prestigious recognition as one of TIME magazine’s Best Inventions of the Year. As we build on our early success, we remain unwavering in our commitment to easing what is often a stressful journey for women undergoing fertility treatments. With this new investment, Calla Lily Clinical Care is poised to transform the landscape of reproductive health by offering dependable, innovative, and patient-friendly drug administration solutions. We look forward to leveraging this momentum to widen our impact, improve lives, and continue setting new standards in clinical care.